Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3BP-5201
- Development stage
- Preclinical
- Lead developer
- RefleXion Medical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
3BP-5201 (also known as RXM-5201) is a peptide-based radiopharmaceutical imaging agent targeting fibroblast activation protein (FAP). Originally developed by 3B Pharmaceuticals, the global rights to 3BP-5201 were acquired by RefleXion Medical to direct its SCINTIX biology-guided radiotherapy system. The agent is designed to be labeled with gallium-68 ($^{68}\text{Ga}$) or fluorine-18 ($^{18}\text{F}$) for positron emission tomography (PET) imaging of FAP expression. FAP is highly expressed on cancer-associated fibroblasts (CAFs) in more than 90% of epithelial solid tumors, making 3BP-5201 a promising pan-tumor imaging agent for both malignant and benign diseases.
- Other names
- [18F]RXM-5201[68Ga]RXM-5201
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 3BP-5201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3BP-5201.